← board
NKTR
Nektar Therapeuticsdistress 8/10 · high distress / dilution risk$68.36-1%today-32% from 52w high
Dermatology 1Immunology / Inflammation 1
Lead: moderate-to-severe atopic dermatitis · target IL-2 · est. market ~$15B (approx, global)
Revenue
$11M
Liquidity
$150M
Runway
0.7 yrs
Shares 1y
+78%
Price & events
+87.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
+2.0%
1W
+2.5%
1M
-25.1%
3M
+84.2%
6M
+173.4%
1Y
+207.9%
2Y
-72.4%
5Y
-74.2%
All
Overview
- Market Cap
- $2.31B
- Volume
- 28.07K
- 52 Week Range
- $21.68 – $100
- Total Shares
- 33.79M
- Float Shares
- 29.14M
- Short %
- 22.52%
- % Held by Insiders
- 0.45%
- % Held by Institutions
- 80.29%
- RVOL
- 0.03x
- Beta
- 1.14
Pipeline stages · 1 programs
RezpegaldesleukinIL-2
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-11-26 | Phase 2 | Rezpegaldesleukinfast track | Alopecia Areata | 94 | active not recruiting |
| 2025-05-06 | Phase 2 | Rezpegaldesleukinfast track | Moderate to Severe Atopic Dermatitis | 396 | active not recruiting |
Catalyst news & presentations · 10
- 2026Guided 40%conferencedata presentationsecondaryPhase 2rezpegaldesleukin · Plan to present REZOLVE-AA results at a medical conference in 2026SEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- second quarter of 2026trial initiationsecondaryPhase 3rezpegaldesleukin · Initiate two Phase 3 registrational trialsSEC 8-K
- early Q2 2026readoutPhase 2rezpegaldesleukin · 16-week extension data from Phase 2b REZOLVE-AA trialSEC 8-K
- Q1 2026readoutPhase 2rezpegaldesleukin · Topline data from maintenance period of REZOLVE-ADSEC 8-K
- 2026-02-10fda agreementrezpegaldesleukin · End of Phase 2 meeting with FDA, alignment on Phase 3 trial design with co-primary endpointsSEC 8-K
- later in 2025conferencedata presentationsecondaryPhase 2rezpegaldesleukin · Submit REZOLVE-AD 16-week induction results for presentation at medical conference.SEC 8-K
- initiate this study in 2025trial initiationsecondaryPhase 2rezpegaldesleukin · Phase 2 randomized, double-blind, placebo-controlled study in approximately 70 adults and children with new onset stage 3 T1DSEC 8-K
- September 18, 2025conferencedata presentationsecondaryPhase 2rezpegaldesleukin · Late-breaker oral presentation at EADV 2025 of REZOLVE-AD Phase 2b induction period resultsSEC 8-K
- 2025-02-24partnershiprezpegaldesleukin · Clinical trial agreement with TrialNet for rezpegaldesleukin in new onset stage 3 type 1 diabetesSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $153 (+124% upside) · 8 analysts
- 2026-05-11WedbushNeutral
- 2026-05-08Piper SandlerOverweight
- 2026-04-21CitigroupBuy
- 2026-04-21WedbushNeutral
- 2026-04-20HC Wainwright & Co.Buy
- 2026-04-20BTIGBuy
Competitors — IL-2
- none identified
Recent news
- 2026-07-22Nektar Therapeutics Initiated at Buy by Canaccord Genuity - Moomoo
- 2026-07-22Nektar Therapeutics (NKTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
- 2026-07-22Nektar (NKTR) Launches Global Trials for Novel Atopic Dermatitis Treatment - GuruFocus
- 2026-07-21Nektar Therapeutics Starts Phase 3 ZENITH AD Program Evaluating Rezpegaldesleukin in Moderate-to-Severe AD - The Dermatology Digest
- 2026-07-21Nektar (NKTR) Launches Global Trials for Novel Atopic Dermatitis Treatment - GuruFocus
- 2026-07-21Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis - PR Newswire
- 2026-07-20Enterprise value to EBIT forward of Nektar Therapeutics – BMV:NKTR - TradingView
- 2026-07-20Nektar Therapeutics (NKTR) Stock Looks Above Fair Value Despite Its 7x Run - simplywall.st
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.